-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Downgrades Atara Biotherapeutics to Hold, Lowers Price Target to $6

Benzinga·01/13/2026 20:17:57
Listen to the news
Canaccord Genuity analyst John Newman downgrades Atara Biotherapeutics (NASDAQ:ATRA) from Buy to Hold and lowers the price target from $25 to $6.